EF Hutton Acquisition Co. I upgraded shares of Artelo Biosciences (NASDAQ:ARTL – Free Report) to a strong-buy rating in a research note released on Tuesday, Zacks.com reports.
Separately, HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Artelo Biosciences in a report on Wednesday, August 14th.
Get Our Latest Stock Report on Artelo Biosciences
Artelo Biosciences Trading Up 1.7 %
Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10. On average, equities research analysts predict that Artelo Biosciences will post -2.41 earnings per share for the current year.
Artelo Biosciences Company Profile
Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
Recommended Stories
- Five stocks we like better than Artelo Biosciences
- ESG Stocks, What Investors Should Know
- When Is the Best Time to Invest in Mutual Funds?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is NVIDIA Stock in a Correction or Consolidation?
- What is Put Option Volume?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.